AbstractApoptosis is a recognized limitation to generating large numbers of megakaryocytes in culture. The genes responsible have been rigorously studied in vivo in mice, but are poorly characterized in human culture systems. As CD34-positive (+) cells isolated from human umbilical vein cord blood were differentiated into megakaryocytes in culture, two distinct cell populations were identified by flow cytometric forward and side scatter: larger size, lower granularity (LLG), and smaller size, higher granularity (SHG). The LLG cells were CD41aHigh CD42aHigh phosphatidylserineLow, had an electron microscopic morphology similar to mature bone marrow megakaryocytes, developed proplatelets, and displayed a signaling response to platelet agonists. The SHG cells were CD41aLowCD42aLowphosphatidylserineHigh, had a distinctly apoptotic morphology, were unable to develop proplatelets, and showed no signaling response. Screens of differentiating megakaryocytes for expression of 24 apoptosis genes identified BCL2L2 as a novel candidate megakaryocyte apoptosis regulator. Lentiviral BCL2L2 overexpression decreased megakaryocyte apoptosis, increased CD41a+ LLG cells, and increased proplatelet formation by 58%. An association study in 154 healthy donors identified a significant positive correlation between platelet number and platelet BCL2L2 mRNA levels. This finding was consistent with the observed increase in platelet-like particles derived from cultured megakaryocytes over-expressing BCL2L2. BCL2L2 also induced small, but significant increases in thrombin-induced platelet-like particle αIIbβ3 activation and P-selectin expression. Thus, BCL2L2 restrains apoptosis in cultured megakaryocytes, promotes proplatelet formation, and is associated with platelet number. BCL2L2 is a novel target for improving megakaryocyte and platelet yields in in vitro culture systems.
Hematopoietic stem cells (HSC) are essential for reconstituting hematopoiesis in the setting of bone marrow (BM) transplantation and are of great value for studies of the basic biology of hematopoiesis. Differentiating HSC into megakaryocytes (MK) in culture has become a standard approach to study megakaryocytopoiesis (MKpoiesis). MK culture systems are also powerful tools for the functional assessment of novel platelet genes, gene variants, protein-coding transcripts, and microRNA associated with platelet reactivity and clinical hemorrhagic or thrombotic disorders. Recent advancements in MKpoiesis research have opened up a new, promising field of ex vivo manufacturing of platelets,41 with the ultimate goal of infusing these products into patients with thrombocytopenia or qualitative platelet disorders. Improvements in this technology may also allow ‘designer’ platelets to be engineered that overcome immunological incompatibility and infection issues.5
A major limitation of all MK culture systems is the relatively short time period for which the differentiating MK can be kept viable before they die through apoptosis.6 The role of apoptosis during MKpoiesis is somewhat controversial,7 with some data supporting a role for the intrinsic pathway of apoptosis in platelet production,108 while other studies show that MK must restrain apoptosis to survive and progress safely through proplatelet formation and platelet generation.1311 However, the apoptosis regulators of human cord blood-derived (CB)-MK cultures remain poorly understood. During the course of our studies with cultured CB MK, we observed two distinct populations of cells by forward and side scatter flow cytometry. The aims of the current study were to determine: (i) whether there were viability and apoptosis differences between these two populations; and (ii) molecular mechanism(s) of apoptosis regulation during Mkpoiesis. We also wanted to begin to identify approaches that would reduce MK apoptosis in order to produce greater yields of MK and platelet in cultures. We demonstrate that the anti-apoptosis Bcl2 family member BCL2L2 (encoding Bcl-w) regulates cultured MK apoptosis, promotes proplatelet formation, and is associated with human platelet number.
Primary megakaryocyte cultures
Human umbilical cord CB was obtained from the New York Blood Center (New York, NY, USA) under institutional review board (IRB) approval (00108527). CD34 hematopoietic stem and progenitor cells (HSPC) were isolated from human umbilical vein CB and cultured in serum free expansion media supplemented with 25 ng/mL of stem cell factor (SCF) and 20 ng/mL of thrombopoietin (TPO) (Peprotech, Rocky Hill, NJ, USA) for six days. Cells were cultured with 50 ng/mL TPO only from days 6-13.14 Adult granulocyte-macrophage colony-stimulating factor (GM-CSF) mobilized CD34 HSPC were purchased from the Utah Cell Therapy and Regenerative Medicine Center (Salt Lake City, UT, USA) under the University of Utah IRB approval (00108527).
Megakaryocyte proplatelet formation assay
Day 9 transduced cells were plated at 2×10 cells/mL in 60μ-Dish Grid-500 plates (Ibidi, Fitchburg, WI, USA) using fresh medium supplemented with 50 ng/mL TPO. On day 13, the proplatelet forming (PPF) MK, defined as displaying at least one filamentous pseudopod, were scored with a light microscope blinded as to experimental group. Images were taken at room temperature under 40× objective, numerical aperture 1.35, using FV1000 confocal laser scanning microscope (Olympus, Center Valley, PA, USA). The percentage of PPF MK was calculated as the number of PPF MK compared to the total number of round cultured cells analyzed. An average 200 cells were counted per condition.
Integrin αIIbβ3 activation assessment
Cells were resuspended in Tyrode’s buffer (138 mM NaCl, 5.5 mM dextrose, 12 mM NaHCO3, 0.8 mM CaCl2, 0.4 mM MgCl2, 2.9 mM KCl2, 0.36 mM Na2HPO4, 20 mM Hepes, pH 7.4). Integrin αIIbβ3 activation was quantified with FITC-labeled PAC1 (1:100) (BD Pharmingen) in response to stimulation15 with no agonist (resting), 100 μM PAR4-AP [GL Biochem (Shanghai) Ltd., China], 250 nM thrombin (Enzyme Research, South Bend, IN, USA) or 10 μg/mL CRP (synthesized at Baylor College of Medicine and cross-linked with glutaraldehyde) for 20 minutes (min) at 37°C, followed by 4% paraformaldehyde fixation at room temperature. Cells were analyzed on a Cytoflex or BD Accuri C6 flow cytometer.
All statistical analyses were performed using GraphPad Prism 6 software version 10.1 (La Jolla, CA, USA) and reported as Mean±Standard Error of Mean (SEM). Fold changes for BCL2L2 levels over time in cultures and for lentiviral overexpression were presented as log2 (fold change) compared to their respective controls (day 6 for changes in BCL2L2 levels over time and empty vector control for overexpression) and analyzed by a one-sample t-test. Log2 transformation was adopted to have a normally distributed fold-change data, determined by Kolmogorov-Smirnov normality test. The relationship between platelet BCL2L2 mRNA expression levels and platelet counts in the 154 healthy human donors in the Platelet RNA Expression Study 1 (PRAX-1) was assessed by Pearson’s correlation with 95% Confidence Interval (95%CI). For all other analyses, statistical significance was assessed using paired Student t-test. P<0.05 was considered statistically significant.
See Online Supplementary Appendix for further details of the experiments.
Subsets of cultured megakaryocytes show differing viability
CD34 cells were isolated from human umbilical vein CB and cultured to generate MK as described previously.14 By day 13, CD34 cells were differentiated into MK, as demonstrated by the expression of mature MK markers (Online Supplementary Figure S1A-D). Day 13 MK were larger than day 0 HSC (Online Supplementary Figure S1E) and demonstrated polyploid MK (Online Supplementary Figure S1F and G). Thus, these culture conditions promoted generation of mature, polyploid MK.
Flow cytometric analysis of day 13 cultures revealed distinct cell populations differing by forward scatter (FSC) and side scatter (SSC) characteristics (Figure 1A): larger MK with lower granularity [larger, lower granular (LLG)] and smaller MK with higher granularity [smaller, higher granular (SHG)]. Peripheral blood (PB) mobilized adult CD34 cells cultured under the same conditions also generated similar subpopulations of MK (Online Supplementary Figure S2). Approximately 80% of LLG MK expressed both CD41a/CD42a and CD41a/CD42b markers, while only 20-30% SHG MK were double positive for mature MK markers (Figure 1B). Lower surface expression of CD42b (GPIbα) in day 13 SHG cells compared to LLG cells is consistent with mitochondrial damage16 as observed in apoptotic adult mobilized HSPC-derived MK.17
Since the numbers of SHG MK showed less differentiation towards mature MK than the LLG MK, and because SHG MK showed reduced CD42b expression, we considered whether SHG MK may have undergone (or be undergoing) apoptosis. Figure 1C shows few CD41a LLG MK-bound annexin V [termed phosphatidylserine (PS)], a marker of apoptosis-induced phosphatidylserine expression, whereas a significantly higher percentage of CD41a SHG MK bound annexin V (termed PS). Anti-annexin V microbeads were used to separate day 13 PS LLG MK from PS SHG MK (purity shown in Online Supplementary Figure S3). Transmission electron microscopy revealed that PS LLG MK exhibited many typical features of BM MK, including large cells with multi-lobed nuclei, mitochondria, granules and surface protrusions (Figure 2A). In contrast, most of the PS SHG MK were apoptotic, displaying membrane blebbing, highly condensed or absent nuclei, and few or no granules (Figure 2B). CD41a LLG MK showed a substantial increase in mitochondrial membrane potential compared to CD41a SHG MK (Figure 1D), further supporting viability of the former.
Several approaches to characterize the functionality of the LLG and SHG MK were undertaken. The signaling capacity of these different MK populations was assessed and LLG, but not SHG, were able to activate integrin αIIbβ3 in response to agonist stimulation (Figure 3A). In addition, thrombin-induced Ca mobilization was observed only in LLG cells but not in SHG cells (Figure 3B). Importantly, by day 13 we observed MK proplatelet formation (PPF). After separating LLG from SHG based on PS exposure, we observed more PPF in PS LLG MK than in PS SHG MK (Figure 3C).
Next, we sought to address whether the LLG population was the origin of the SHG cells. Day 13 PS LLG MK were isolated and labeled with lipophilic cell tracking dye DiO1918 and cultured for an additional 48 hours (h) to follow the ‘movement’ of the DiO label to SHG MK (Figure 3D). We observed an increase in DiO LLG MK at day 15 (Figure 3E). More importantly for this experiment, significantly more SHG MK contained tracking dye after an additional two days in culture (Figure 3E). These data indicate that CB-derived MK cultures represent a continuum of cells transitioning from mature viable CD41a CD42a PS functional LLG MKs into CD41a CD42a PS apoptotic SHG MK.
BCL2L2 regulates megakaryocyte apoptosis and larger, lower granular megakaryocyte number
To begin to understand the molecular mechanisms regulating cultured MK apoptosis, we screened 24 genes with established roles in intrinsic and extrinsic apoptosis pathways whose expression changed as MK matured in culture. Because the percentages of SHG MK substantially increased between day 6 and day 13 (Online Supplementary Figure S4), we performed gene expression profiling on CD61-purified MK at these time points and observed a 3-fold and 12-fold increase, respectively, in BCL2L1 and BCL2L2, two anti-apoptotic Bcl-2 family members (Figure 4A). BCL2L1 encodes Bcl-xL and has an established role in MKpoiesis.201312 However, BCL2L2 (encoding Bcl-w) has not been studied in Mkpoiesis and became the focus of further investigation. The increase in expression of BCL2L2 observed by RNA sequencing was verified by qPCR on RNA isolated from CD61-purified MK (Figure 4B). This led to the hypothesis that those MK with increasing levels of anti-apoptotic BCL2L2 would be the LLG, whereas those MK with stable or decreasing levels of anti-apoptotic BCL2L2 would be the SHG. LLG MK and SHG MK were purified by cell sorting and analyzed for changes in BCL2L2 expression over time in culture. There was no difference between LLG and SHG cells for BCL2L2 expression at days 6 and 9, but a significant difference was observed by day 13 due to a fall in BCL2L2 in SHG cells and concomitant rise in LLG cells (Figure 4C).
We next considered the effects of BCL2L2 on cultured MK apoptosis and number. Initially, we used the general Bcl-2 family inhibitor, ABT-263, to screen for an effect on CD41a LLG MK numbers, and observed a significant reduction (Online Supplementary Figure S5). Since ABT-263 inhibits all Bcl-2 family members, we specifically tested the effects of BCL2L2 on the cultured MK. CB-derived MK cultures were transduced with lentiviral vectors containing BCL2L2, and both mRNA and protein increased by day 13 (Figure 5A-C). BCL2L2 overexpression significantly reduced the percentage of annexin V CD41a MK (Figure 5D) and increased the number of CD41a LLG MK by 19% (1.36×10 to 1.61×10; P=0.049).
BCL2L2 regulates megakaryocyte proplatelet formation
Megakaryocyte PPF is believed to be a critical process in thrombopoiesis. By day 13 we observed MK PPF primarily in LLG MK (Figure 3C), and asked whether Bcl-w might affect PPF. Importantly, when we scored MK PPF blinded to lentiviral transduction treatment group, we found that BCL2L2 overexpression induced a significant 58% increase in PPF MK (Figures 5E and F).
Relationship between BCL2L2 expression and platelet number
Megakaryocyte PPF is tightly linked to PB platelet count,222110 raising the possibility that BCL2L2 may regulate platelet number as well as MKpoiesis. Because we had previously performed genome-wide platelet gene expression profiling in 154 healthy individuals,14 we were able to query this dataset for such an association. Platelet BCL2L2 mRNA levels were positively correlated with platelet count in the PRAX1-1 study (Figure 6A).
As is typical of MK culture systems, the day 13 cultures also contained a population of small, hypogranular particles that overlapped the forward and side scatter properties of normal human platelets (Figure 6B). These particles are typically referred to as platelet-like particles (PLP), and we assessed the effect of MK BCL2L2 overexpression on PLP number and function. Compared to control lentiviral transduction, BCL2L2 overexpression induced a modest but significant increase in CD41a PLP from approximately 10% to approximately 19% (Figure 6C), suggesting BCL2L2 enables mature platelet production.
Platelet-like particles were stimulated with thrombin to assess their ability to activate αIIbβ3 and release α-granules. PLP from both control and BCL2L2 lentiviral constructs demonstrated cell activation above background (Figure 5D and E, and flow cytometry plots in Online Supplementary Figure S6); the signal was small but consistent in PLP with control lentivirus. Importantly, among these CD41a and CD42a PLP, MK BCL2L2 overexpression enhanced thrombin-induced activation compared to control lentivirus (Figure 6D and E, and flow cytometry plots in Online Supplementary Figure S6). PAC1 binding and P-selectin expression in PLP treated with buffer instead of thrombin were not altered by BCL2L2 overexpression (data not shown).
There has been exciting progress in the generation of MK and platelets via the use of induced pluripotent stem cells, immortalized MK cell lines, and bioreactors,24231 but cultured human CB MK remain an important tool for gaining a deeper understanding of MKpoiesis and platelet production. Apoptosis of MK in a culture system remains a major obstacle to progress in the in vitro generation of MK and platelets.6 A great deal of our understanding about the apoptosis genes regulating MKpoiesis and PB platelet number is derived from work in murine systems,27252012 while relatively less is known about in vitro cultured MK apoptosis. The major finding in the current study is that the pro-survival gene BCL2L2 restrains apoptosis in cultured human MK, regulates PPF, and is associated with platelet number in healthy humans. We also found that suspensions of CB-derived MK are a useful system for assessing candidate gene function by flow cytometric analysis, and that BCL2L2 overexpression induced increases in agonist-induced signaling responses in PLP. BCL2L2 thus becomes another potential target for enhancing MK yields in vitro, which may benefit both basic research on MKpoiesis and the long-term goal of producing platelets for transfusion into patients.
Two distinct populations of cells invariably emerged during our CB MK cultures that were easily distinguished by flow cytometry logarithmic scale forward and side scatter measures. Electron microscopic analysis of the LLG MK (Figure 2) demonstrated they were most similar to primary BM MK, and resembled those observed by Cramer et al.28 and Chantelot-Bellanne et al.29 In contrast, the SHG population represented primarily apoptotic cells resembling the senescent MK observed by Radley et al., where the nucleus fragmented but the cells appeared to change shape and ‘round up’ rather than fragment.30 Membrane degradation during apoptosis likely contributed to the loss of MK markers (Figure 1B). The most important functional differences between LLG and SHG were the ability to form proplatelets and ‘signal’ in response to platelet agonists (Figure 2A-C). It is worth noting that although PS-positivity marked apoptotic SHG MK, some fraction of LLG MK were also capable of PS exposure in response to thrombin stimulation (Online Supplementary Figure S7), perhaps akin to collagen and thrombin activated (COAT) platelets.3331 Thus, simple gating on flow cytometric forward and side scatter measurements, without the need for fluorescently-labeled antibodies, identified functional MK and can improve signal-to-noise read-outs that test the functionality of candidate MK/platelet genes.
Apoptosis was established as a mechanism for platelet lifespan by the Kile laboratory when they showed that the balance between Bcl-xL and Bak regulate murine lifespan in vivo.20 The pro-survival Bcl-2 family member Bcl-xL degrades in aging platelets, thus allowing apoptosis to proceed. In addition to Bcl-xL, the Bcl-2 family includes Bcl-2, Mcl-1 and Bcl-w, which are encoded by BCL2, MCL1 and BCL2L2, respectively. Altered murine expression of pro-survival Bcl-2 family members has shown variable effects on platelet number. Global chimeric vav-Bcl2 overexpression resulted in normal MK numbers but an approximately 50% reduction in platelet counts,34 whereas MK-specific deletion of Bcl2 had no effect on platelet number.35 MK-specific deletion of Bcl2l1 deletion caused MK apoptosis, loss of platelet shedding, and a macrothrombocy-topenia.12 MK-specific deletion of Mcl1 did not affect MK number or morphology, or platelet count or volume.13 Print et al. globally inactivated Bcl2l2 to study its importance in murine physiology.36 Although Mkpoiesis was not a major focus of their study, they reported that three Bcl2l2−/− mice displayed numbers of MK colony-forming cells and platelets comparable to three wild-type litter-mates. This latter report appears to differ from our finding in primary human MK and platelets, where BCL2L2 increased during MK differentiation, overexpression of BCL2L2 increased the numbers of both the viable CD41a LLG MK and MK PPF (Figure 4E and F), and BCL2L2 levels correlated with platelet number (Figure 5A). This apparent discrepancy between human and mouse regarding the effect of BCL2L2 on MKpoiesis and platelet production could be due to a compensatory upregulation of other Bcl-2 family members in the Bcl2l2 null mice. Alternatively, small numbers of mice and different conditions may have led to a chance finding in the Print et al. study,36 but there also may be species differences in the relative importance of BCL2L2 because human platelets contain 3.6-fold higher levels of BCL2L2 transcripts than mouse platelets.37
We showed that the SHG MK were derived from the LLG MK (Figure 2D and E), supporting a process by which viable LLG avoid apoptosis long enough to mature and acquire mature MK markers, but an unknown trigger induces some cells to become dying SHG. The day 9 to day 13 increase in BCL2L2 is expected to restrain apoptosis in LLG cells, whereas BCL2L2 reduction should enable apoptosis to proceed in SHG cells (Figure 3C). Perhaps a yet-to-be-defined switch regulates BCL2L2 levels after day 9 in cultured cells. CB-derived LLG MK began to develop proplatelet extension around day 12 and peaked at days 13-15, similar to what had been reported by Balduini et al.38 Because SHG appear days before PPF MK (Online Supplementary Figure S4), they do not seem to be ‘exhausted’ MK post release of proplatelets.
Sim et al. used adult mobilized HSPC to culture MK that also gave rise to populations of functional and apoptotic MK.17 Our work differs from this primarily by studying the molecular mechanism of apoptosis. We are unaware of direct comparisons among any source of MK (neonatal, adult, murine, embryonic stem cells, etc.) in terms of the degree of apoptosis in culture, but it is reasonable to consider that some molecular mechanisms will be shared. In this regard, our data show no statistically significant difference between BCL2L2 levels in neonatal and adult MK (P>0.47), and adult MK also display more PPF with BCL2L2 overexpression (Online Supplementary Figure S8). As with MK, there is no statistically significant difference between BCL2L2 levels in neonatal and adult platelets.39
The finding of a significant positive correlation between human platelet BCL2L2 levels and PB platelet counts (Figure 5A) supports a mechanism whereby Bcl-w increases MK PPF which causes increased blood platelets. Numerous apoptosis genes have been studied for effects on Mkpoiesis.414019138 We observed that pro-apoptotic genes BAX and BAK1 showed little to no change in expression from day 6 to day 13 in MK cultures (Online Supplementary Figure S9A and B). However, similar to BCL2L2, anti-apoptotic gene BCL2L1 showed increased expression in LLG over time, and was higher at day 13 in LLG compared to SHG (Online Supplementary Figure S9C). Taken together, these studies suggest BCL2L1 and BCL2L2 restrain apoptosis and that this may be the key mechanism for prolonging MK survival in the late stages of differentiation in culture. We cannot exclude a role for other apoptosis genes in Mkpoiesis and platelet production. It is also reasonable to consider that, like Bcl-xL and Bak, Bcl-w may also impact the life span of the human PB platelet.20 However, additional studies are needed to address this possibility.
The BCL2L2-induced increase in MK PPF led to experiments assessing production of PLP. BCL2L2 overexpression roughly doubled the number of CD41a PLP and increased the ability of these PLP to show a functional response when activated with thrombin (Figure 5C-E). However, we did not observe any significant correlation between in vivo BCL2L2 expression with other platelet agonists such as ADP, PAR1-AP and PAR4-AP (www.Plateletomics.com, as reported by Simon et al.40). Nevertheless, we would emphasize that the percentages of functional PLP were small, although consistent and statistically significant.
Our findings have several research and clinical implications. Firstly, we have shown that simple gating on flow cytometric forward and side scatter measurements allows the identification of the subset of viable and functional MK. This approach represents a substantial improvement in the signal-to-noise read-outs to test the functionality of candidate MK/platelet genes identified in GWAS. Secondly, promotion of apoptosis by inhibiting of Bcl-2 family members is under investigation for the treatment of a variety of malignancies;4341 a limiting toxicity has been thrombocytopenia.4342 Bcl-2 family members, MCL1 and BCL2L1 are the most frequently amplified in 26 tumor types,4544 whereas BCL2L2 amplification is rare.46 Perhaps selective targeting of Bcl-2 family members that spares Bcl-w could minimize thrombocytopenia. Lastly, progress toward the manufacture of in vitro platelets may benefit from the pro-survival benefits on MK generation and PPF of Bcl-w. BCL2L2 overexpression may have synergistic or additive effects when used in combination with an antagonist of the aryl hydrocarbon receptor (StemRegenin 1), BCL2L1 overexpression, abscisic acid, and other factors that have been shown to increase numbers of proplatelet-forming MK in culture.48471
The authors also thank the University of Utah Flow Cytometry Facility in addition to the National Cancer Institute through Award Number 5P30CA042014-24.
- FundingThis study was supported by a grant from the National Institutes of Health National Heart, Lung and Blood Institute (HL116713) and funding from the Cardeza Foundation of Hematologic Research. The authors thank Ms. Lin Ma, Thomas Jefferson University, and Ms. Sarah Hugo, University of Utah for their help isolating cord blood stem cells; Dr. Xianguo Kong, Thomas Jefferson University for designing lentiviral vectors; Ms. Diana Lim, Molecular Medicine Program from University of Utah, for drafting the figures and consultation on data display.
- Check the online version for the most updated information on this article, online supplements, and information on authorship & disclosures: www.haematologica.org/content/104/10/2075
- Received August 16, 2018.
- Accepted January 30, 2019.
- Ito Y, Nakamura S, Sugimoto N. Turbulence Activates Platelet Biogenesis to Enable Clinical Scale Ex Vivo Production. Cell. 2018; 174(3):636-648.e18. PubMedhttps://doi.org/10.1016/j.cell.2018.06.011Google Scholar
- Moreau T, Evans AL, Vasquez L. Large-scale production of megakaryocytes from human pluripotent stem cells by chemically defined forward programming. Nat Commun. 2016; 7:11208. PubMedhttps://doi.org/10.1038/ncomms11208Google Scholar
- Nakamura S, Takayama N, Hirata S. Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells. Cell Stem Cell. 2014; 14(4):535-548. PubMedhttps://doi.org/10.1016/j.stem.2014.01.011Google Scholar
- Thon JN, Dykstra BJ, Beaulieu LM. Platelet bioreactor: accelerated evolution of design and manufacture. Platelets. 2017; 28(5):472-477. Google Scholar
- Zhang N, Zhi H, Curtis BR. CRISPR/Cas9-mediated conversion of human platelet alloantigen allotypes. Blood. 2016; 127(6):675-680. PubMedhttps://doi.org/10.1182/blood-2015-10-675751Google Scholar
- Zauli G, Vitale M, Falcieri E. In vitro senescence and apoptotic cell death of human megakaryocytes. Blood. 1997; 90(6):2234-2243. PubMedGoogle Scholar
- Kile BT. The role of apoptosis in megakaryocytes and platelets. Br J Haematol. 2014; 165(2):217-226. PubMedhttps://doi.org/10.1111/bjh.12757Google Scholar
- Morison IM, Cramer Borde EM, Cheesman EJ. A mutation of human cytochrome c enhances the intrinsic apoptotic pathway but causes only thrombocytopenia. Nat Genet. 2008; 40(4):387-389. PubMedhttps://doi.org/10.1038/ng.103Google Scholar
- Kaluzhny Y, Yu G, Sun S. BclxL overexpression in megakaryocytes leads to impaired platelet fragmentation. Blood. 2002; 100(5):1670-1678. PubMedhttps://doi.org/10.1182/blood-2001-12-0263Google Scholar
- De Botton S, Sabri S, Daugas E. Platelet formation is the consequence of caspase activation within megakaryocytes. Blood. 2002; 100(4):1310-1317. PubMedhttps://doi.org/10.1182/blood-2002-03-0686Google Scholar
- Kodama T, Takehara T, Hikita H. BH3-only activator proteins Bid and Bim are dispensable for Bak/Bax-dependent thrombo-cyte apoptosis induced by Bcl-xL deficiency: molecular requisites for the mitochondrial pathway to apoptosis in platelets. J Biol Chem. 2011; 286(16):13905-13913. PubMedhttps://doi.org/10.1074/jbc.M110.195370Google Scholar
- Josefsson EC, James C, Henley KJ. Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med. 2011; 208(10):2017-2031. PubMedhttps://doi.org/10.1084/jem.20110750Google Scholar
- Debrincat MA, Josefsson EC, James C. Mcl-1 and Bcl-x(L) coordinately regulate megakaryocyte survival. Blood. 2012; 119(24):5850-5858. PubMedhttps://doi.org/10.1182/blood-2011-12-398834Google Scholar
- Edelstein LC, Simon LM, Montoya RT. Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c. Nat Med. 2013; 19(12):1609-1616. PubMedhttps://doi.org/10.1038/nm.3385Google Scholar
- Faraday N, Rade JJ, Johns DC. Ex vivo cultured megakaryocytes express functional glycoprotein IIb-IIIa receptors and are capable of adenovirus-mediated transgene expression. Blood. 1999; 94(12):4084-4092. PubMedGoogle Scholar
- Bergmeier W, Burger PC, Piffath CL. Metalloproteinase inhibitors improve the recovery and hemostatic function of in vitro-aged or -injured mouse platelets. Blood. 2003; 102(12):4229-4235. PubMedhttps://doi.org/10.1182/blood-2003-04-1305Google Scholar
- Sim X, Jarocha D, Hayes V. Identifying and enriching the platelet-producing human stem cell-derived megakaryocytes using factor V uptake. Blood. 2017; 130(2):192-204. PubMedhttps://doi.org/10.1182/blood-2017-01-761049Google Scholar
- Parish CR. Fluorescent dyes for lymphocyte migration and proliferation studies. Immunol Cell Biol. 1999; 77(6):499-508. PubMedhttps://doi.org/10.1046/j.1440-1711.1999.00877.xGoogle Scholar
- Ragnarson B, Bengtsson L, Haegerstrand A. Labeling with fluorescent carbocyanine dyes of cultured endothelial and smooth muscle cells by growth in dye-containing medium. Histochemistry. 1992; 97(4):329-333. PubMedhttps://doi.org/10.1007/BF00270034Google Scholar
- Mason KD, Carpinelli MR, Fletcher JI. Programmed anuclear cell death delimits platelet life span. Cell. 2007; 128(6):1173-1186. PubMedhttps://doi.org/10.1016/j.cell.2007.01.037Google Scholar
- Beauchemin H, Shooshtarizadeh P, Vadnais C, Vassen L, Pastore YD, Moroy T. Gfi1b controls integrin signaling-dependent cytoskeleton dynamics and organization in megakaryocytes. Haematologica. 2017; 102(3):484-497. PubMedhttps://doi.org/10.3324/haematol.2016.150375Google Scholar
- Machlus KR, Johnson KE, Kulenthirarajan R. CCL5 derived from platelets increases megakaryocyte proplatelet formation. Blood. 2016; 127(7):921-926. PubMedhttps://doi.org/10.1182/blood-2015-05-644583Google Scholar
- Thon JN, Mazutis L, Wu S. Platelet bioreactor-on-a-chip. Blood. 2014; 124(12):1857-1867. PubMedhttps://doi.org/10.1182/blood-2014-05-574913Google Scholar
- Sugimoto N, Eto K. Platelet production from induced pluripotent stem cells. J Thromb Haemost. 2017; 15(9):1717-1727. https://doi.org/10.1111/jth.13736Google Scholar
- McArthur K, Chappaz S, Kile BT. Apoptosis in megakaryocytes and platelets: the life and death of a lineage. Blood. 2018; 131(6):605-610. PubMedhttps://doi.org/10.1182/blood-2017-11-742684Google Scholar
- Schoenwaelder SM, Jarman KE, Gardiner EE. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood. 2011; 118(6):1663-1674. PubMedhttps://doi.org/10.1182/blood-2011-04-347849Google Scholar
- White MJ, Schoenwaelder SM, Josefsson EC. Caspase-9 mediates the apoptotic death of megakaryocytes and platelets, but is dispensable for their generation and function. Blood. 2012; 119(18):4283-4290. PubMedhttps://doi.org/10.1182/blood-2011-11-394858Google Scholar
- Cramer EM, Norol F, Guichard J. Ultrastructure of platelet formation by human megakaryocytes cultured with the Mpl ligand. Blood. 1997; 89(7):2336-2346. PubMedGoogle Scholar
- Bellanne-Chantelot C, Schmaltz-Panneau B, Marty C. Mutations in the SRP54 gene cause severe congenital neutropenia as well as Shwachman-Diamond-like syndrome. Blood. 2018; 132(12):1318-1331. PubMedhttps://doi.org/10.1182/blood-2017-12-820308Google Scholar
- Radley JM, Haller CJ. Fate of senescent megakaryocytes in the bone marrow. Br J Haematol. 1983; 53(2):277-287. PubMedhttps://doi.org/10.1111/j.1365-2141.1983.tb02022.xGoogle Scholar
- Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL. Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood. 2000; 95(5):1694-1702. PubMedGoogle Scholar
- Dale GL, Friese P, Batar P. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature. 2002; 415(6868):175-179. PubMedhttps://doi.org/10.1038/415175aGoogle Scholar
- Jobe SM, Leo L, Eastvold JS. Role of FcRgamma and factor XIIIA in coated platelet formation. Blood. 2005; 106(13):4146-4151. PubMedhttps://doi.org/10.1182/blood-2005-03-1223Google Scholar
- Ogilvy S, Metcalf D, Print CG, Bath ML, Harris AW, Adams JM. Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci U S A. 1999; 96(26):14943-14948. PubMedhttps://doi.org/10.1073/pnas.96.26.14943Google Scholar
- Debrincat MA, Pleines I, Lebois M. BCL-2 is dispensable for thrombopoiesis and platelet survival. Cell Death Dis. 2015; 6:e1721. PubMedhttps://doi.org/10.1038/cddis.2015.97Google Scholar
- Print CG, Loveland KL, Gibson L. Apoptosis regulator bcl-w is essential for spermatogenesis but appears otherwise redundant. Proc Natl Acad Sci U S A. 1998; 95(21):12424-12431. PubMedhttps://doi.org/10.1073/pnas.95.21.12424Google Scholar
- Rowley JW, Oler AJ, Tolley ND. Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. Blood. 2011; 118(14):e101-111. PubMedhttps://doi.org/10.1182/blood-2011-03-339705Google Scholar
- Balduini A, Pallotta I, Malara A. Adhesive receptors, extracellular proteins and myosin IIA orchestrate proplatelet formation by human megakaryocytes. J Thromb Haemost. 2008; 6(11):1900-1907. PubMedhttps://doi.org/10.1111/j.1538-7836.2008.03132.xGoogle Scholar
- Caparros-Perez E, Teruel-Montoya R, Lopez-Andreo MJ. Comprehensive comparison of neonate and adult human platelet transcriptomes. PLoS One. 2017; 12(8):e0183042. Google Scholar
- Simon LM, Edelstein LC, Nagalla S. Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics. Blood. 2014; 123(16):e37-45. PubMedhttps://doi.org/10.1182/blood-2013-12-544692Google Scholar
- Oltersdorf T, Elmore SW, Shoemaker AR. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-681. PubMedhttps://doi.org/10.1038/nature03579Google Scholar
- Roberts AW, Seymour JF, Brown JR. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012; 30(5):488-496. PubMedhttps://doi.org/10.1200/JCO.2011.34.7898Google Scholar
- Wilson WH, O’Connor OA, Czuczman MS. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010; 11(12):1149-1159. PubMedhttps://doi.org/10.1016/S1470-2045(10)70261-8Google Scholar
- De Blasio A, Vento R, Di Fiore R. Mcl-1 targeting could be an intriguing perspective to cure cancer. J Cell Physiol. 2018; 233(11):8482-8498. Google Scholar
- Beroukhim R, Mermel CH, Porter D. The landscape of somatic copy-number alteration across human cancers. Nature. 2010; 463(7283):899-905. PubMedhttps://doi.org/10.1038/nature08822Google Scholar
- Cerami E, Gao J, Dogrusoz U. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5):401-404. PubMedhttps://doi.org/10.1158/2159-8290.CD-12-0095Google Scholar
- Malara A, Fresia C, Di Buduo CA. The Plant Hormone Abscisic Acid Is a Prosurvival Factor in Human and Murine Megakaryocytes. J Biol Chem. 2017; 292(8):3239-3251. PubMedhttps://doi.org/10.1074/jbc.M116.751693Google Scholar
- Strassel C, Brouard N, Mallo L. Aryl hydrocarbon receptor-dependent enrichment of a megakaryocytic precursor with a high potential to produce proplatelets. Blood. 2016; 127(18):2231-2240. PubMedhttps://doi.org/10.1182/blood-2015-09-670208Google Scholar